Search Results
Results found for "Tao Che"
- FDA Approval Is a Strategy Obstacle, Not a Paperwork Problem
✅ FDA approval is not a documentation checkpoint. It’s a strategic filter. However, that sequence conceals a significant flaw; it treats FDA approval as the final checkpoint , But approval is not a checkpoint. ✅ It’s a strategic mirror.
- Using Live-cell High-Content Screening to Characterize CB2 Ligands: Insights From 16 Synthetic Cannabinoids
conformations, and non-specific interactions introduce noise at precisely the stage where medicinal chemistry SCRAs—although often known for their undesired toxicological profile—offer a chemically diverse set of Furthermore, image-based data provide an additional check against off-target cytotoxicity or morphological Ki values were then calculated using the Cheng–Prusoff equation, with CELT-331 parameters fully reported European Journal of Medicinal Chemistry, 46(2), 547–555.
- How System-Level GPCR Thinking Prevents Discovery Failures
GPCR Podcast: Chemical Probes for GPCR Imaging with Dr. His work shows why chemical design can outperform antibodies and how rigorous assay validation bridges chemistry and biology effectively.
- How to Avoid the Most Common Gaps in Your Biotech Pitch
But behind the polite nods, your audience is checking out.
- GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures
Kenakin drew a sharp contrast between chemically reactive irreversible inhibitors and pseudo-irreversible Ranking Partial Agonists Without Losing Meaning Chemists want a single number. These GPCR pharmacology insights are essential for directing chemistry toward the property that actually
- High-Content Screening for GPCR Programs: Overcoming Assay Limitations with Fluorescent Ligands
automated microscopy, multiplexed imaging, and computational analysis to evaluate cellular responses under chemical
- How a Failed Experiment Created a Powerful GPCR Imaging Tool
Episode #177 The Experiment That Was Never Meant to Succeed When David Hodson’s lab teamed up with chemist Hodson: physiology, disease context, and imaging logic JB: chemistry, ligand engineering, mechanistic Collaboration, Chemistry, and the Pivot That Changed the Project Goal: Develop a photo-switchable GPCR
- From Farm Fields to GPCR Discovery, GLP-1 and GIP
Enter a long-term collaboration with chemist Dr.
- Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism
Here, the Schild plot becomes a diagnostic tool rather than a checkbox test: Slopes >1 often mean incomplete
- How Schild Analysis Protects Your Conclusions in GPCR Research
David Hodson walks through how his team uses fluorescence tools and chemically engineered ligands to listen Researchers navigating complex datasets, balancing innovation with assay rigor, or working across chemistry–pharmacology–physiology
- From Lab Logic to Leadership: How Scientific Thinking Holds Back Biotech Operations
Here are three questions to help you check in with yourself: 1️⃣ Do you delay or dilute decisions while
- GPCR Collaboration: From Models to Medicine
GPCRs demanded something different: the integration of modeling, medicinal chemistry, and pharmacology Predictions from modeling inform chemistry. Chemistry fuels assays. Chemists understand why certain molecules are worth the effort to synthesize. Medicinal chemists can synthesize molecules, but must choose carefully from infinite possibilities. in mind, chemistry connected to assays, and assay data cycling back to refine predictions.
- Accelerating GPCR Drug Discovery: What 40 Years of Pharmacology Reveal
Modern real-time assays can deliver these insights earlier, faster, and cheaper than most teams assume Programs aren’t killed because of bad ideas—they’re paused when the chemical matter isn’t compelling
- Enhancing GPCR Research Outreach | Dr GPCR University early-bird registration ends soon!
assays in drug discovery October 2024 | Biologics US 2024 October 2 - 4, 2024 | 9th GPCRs in Medicinal Chemistry
- From Failed Experiments to Predictive GPCR Models
Collaborating with chemists, biologists, and pharmacologists not only made his predictions more useful Today, his group includes around ten computational chemists and one in-house medicinal chemist. This is when the synthetic expertise of the chemist becomes essential. Carlsson notes that it’s easier to find pharmacologists to run assays than it is to persuade chemists
- Innovative Data-Driven Solutions: The pHSense Revolution
It was the result of chemistry, collaboration, and relentless effort until the signal finally confirmed The Chemistry That Almost Didn’t Work Designing pH-sensitive rare-earth complexes was not an obvious The chemistry involved is notoriously complex. Solubility poses significant challenges. The chemistry originated from Parker’s lab. What started as a chemistry problem has evolved into a discovery platform.
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
cell function Protein Biochemist/Structural Biologist Senior Scientist/Staff Scientist, Computational Chemistry
- Transformative GPCR Insights: Unleash New Horizons in Science | Sep 9 - 15, 2024
GPCR-targeted drug development, incorporating machine learning, innovative biophysical methods, and medicinal chemistry The full agenda is now available; check it here ! Discovery on Target October 2024 | Biologics US 2024 October 2 - 4, 2024 | 9th GPCRs in Medicinal Chemistry function NEW Protein Biochemist/Structural Biologist Senior Scientist/Staff Scientist, Computational Chemistry (5-HT2A) GPCRs in Oncology and Immunology The power of many: Multilevel targeting of representative chemokine
- Dr. GPCR Updates
This partnership aims to bring advanced chemical probe strategies to the forefront.
- New Tools, Smart Signals, and The Kenakin Brief
Explore Terry's Corner From Chemistry Lab to GPCR Partner – New Podcast with Celtarys Dr. Maria Majellaro of Celtarys shares how her team translates medicinal chemistry into practical GPCR assay
- How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs
of Discovery pHSense wasn’t built in a vacuum—it was born from decades of groundwork in rare earth chemistry It’s the product of layered collaborations—with Durham University chemist David Parker on the probe chemistry
- Understanding Enzyme Inhibition In GPCR Discovery Programs
year of expert training Unlock On-Demand Yearly Access Now — Premium Members Get Over 50% Discount at Checkout
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
Seemed Like Magic Before modern pharmacology, enzymes were mysterious catalysts that seemed to defy chemical In this lecture, you’ll revisit the early days of discovery: when scientists thought cellular chemistry isn’t a checkbox; it’s a survival test. Yet many discovery teams still relegate them to the “ADME” checklist, rather than the strategic design
- Assay Volume Control: Your GPCR Drug Discovery Power Lever
months of expert training Unlock On-Demand Yearly Access Now — Premium Members Get Over 50% Discount at Checkout updates, priority event alerts, vetted jobs, and commentary that connects dots across pharmacology, chemistry
- The Truth About GPCR Product Launches: Years in the Making
It started not with biology—but with chemistry. Revvity and academic collaborator Prof. Mini Timeline: The Road to pHSense → Initial lanthanide probe design with Durham University (chemistry Revnity’s partnership with Durham (chemistry) and the Institute of Functional Genomics in Montpellier
- Assay Sensitivity: The Hidden Lever Driving GPCR Drug Discovery
Adjusting assay sensitivity—whether through expression systems, chemical modulation, or engineered desensitization—provides
- Orthosteric vs Allosteric Interactions— and the pHSense Shift in Internalization
GPCR members save 50%+ (check your Weekly News code). Years of chemistry, photophysics, and pharmacology condensed into one breakthrough: pHSense , a reagent Rare-earth europium complexes offered potential—but the chemistry was brutal. They translated a fundamental principle of chemistry into a usable platform for pharmacology—showing how persistence, precision, and the courage to take on “impossible” chemistry can shift the entire GPCR
- Orthosteric vs. Allosteric Interactions: The Silent Decider of Safety and Success
GPCR members save 50%+ (check your Weekly News code).
- Optimizing HTRF Assays with Fluorescent Ligands: Time-Resolved Fluorescence in GPCR Research
By combining deep expertise in GPCR biology with advanced fluorescence chemistry, Celtarys custom-developed Curr Chem Genomics. 2009 May 28;3:22-32. doi: 10.2174/1875397300903010022.
- Targeting GPCRs in the CNS: Advances in Drug Discovery Strategies
Chem Rev. 2017 Jan 11;117(1):139-155. Chem Rev. 2017 Jan 11;117(1):139-155. doi: 10.1021/acs.chemrev.6b00177 Alavi MS, Shamsizadeh A, Azhdari-Zarmehri






























